Previously recorded as Beijing Biocytogen Co., Ltd. (to 2021)
37 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Biocytogen Pharmaceuticals (Beijing) Co., Ltd. portfolio ends in Jun 2037, and more of its terms end in 2037 (14) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2037
Next term end
27
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2040 · High confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Nov 2039 · High confidence
Also notable
Ends Jun 2037 · High confidence
Also notable
Ends Dec 2038 · High confidence
Also notable
Ends Aug 2037 · High confidence
Genetically Modified Non-Human Animals with Humanized Immunoglobulin Locus
US 11,730,151
Granted 2023. Computed term ends 2040.
Immunodeficient Non-Human Animal
US 10,820,580
Granted 2020. Computed term ends 2038.
Genetically Modified Mice Expressing Humanized CD47
US 10,918,095
Granted 2021. Computed term ends 2038. A terminal disclaimer caps this term to an earlier patent's.
GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa
US 10,973,212
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
ANTI-PD-1 Antibodies and Uses Thereof
US 11,352,429
Granted 2022. Computed term ends 2039.
Genetically Modified Mice Expressing Humanized PD-1
US 10,912,287
Granted 2021. Computed term ends 2037. A terminal disclaimer caps this term to an earlier patent's.
GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
US 10,945,420
Granted 2021. Computed term ends 2038.
Genetically Modified Non-Human Animal with Human or Chimeric PD-L1
US 11,317,611
Granted 2022. Computed term ends 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 15 to 22, 2027 · next Feb 15
- 1 fee due Nov 21, 2027The maintenance fee for Modified Immunoglobulins (US 11,987,615) comes due Nov 21, 2027. Unpaid by May 22, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
What they patent
The largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,912,287 | Genetically Modified Mice Expressing Humanized PD-1 In force · High confidence | In force | High confidence | |
| US 11,234,420 | Method for Constructing PD-1 Gene Modified Humanized Animal Model and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,945,418 | Genetically Modified Non-Human Animal with Human or Chimeric PD-L1 In force · High confidence | In force | High confidence | |
| US 11,071,290 | Genetically Modified Non-Human Animal with Human or Chimeric CTLA-4 In force · High confidence | In force | High confidence | |
| US 11,096,383 | Method of Using a Genetically Modified Mouse That Expresses a Humanized CTLA-4 Gene In force · High confidence | In force | High confidence | |
| US 11,279,948 | Genetically Modified Non-Human Animal with Human or Chimeric OX40 In force · High confidence | In force | High confidence | |
| US 11,317,611 | Genetically Modified Non-Human Animal with Human or Chimeric PD-L1 In force · High confidence | In force | High confidence | |
| US 11,464,876 | Genetically Modified Mouse Comprising a Chimeric Tigit In force · High confidence | In force | High confidence | |
| US 11,505,806 | Genetically Modified Non-Human Animal with Human or Chimeric OX40 In force · High confidence | In force | High confidence | |
| US 11,534,502 | Genetically Modified Non-Human Animal with Human or Chimeric TIGIT In force · High confidence | In force | High confidence |
Also on record, not counted in the 37: 59 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.